Ironwood Pharmaceuticals (IRWD) Invested Capital (2009 - 2026)

Ironwood Pharmaceuticals has disclosed Invested Capital across 18 years of filings, most recently posting -$17.3 million for Q1 2026.

• Invested Capital for Q1 2026 came in at -$17.3 million, up 94.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.3 million (up 94.82% YoY), and the FY2025 annual result was -$62.2 million, up 79.37% from the prior year.
• Invested Capital came in at -$17.3 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$62.2 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $706.9 million in Q1 2023 to a low of -$334.1 million in Q1 2025.
• The 5-year median for Invested Capital is -$64.7 million (2025), against an average of $81.9 million.
• Across the five-year window, Invested Capital surged 479.32% in 2022 and sank 253.33% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Invested Capital stood at $652.4 million in 2022, then plunged by 69.87% to $196.5 million in 2023, then tumbled by 253.33% to -$301.3 million in 2024, then soared by 79.37% to -$62.2 million in 2025, then jumped by 72.18% to -$17.3 million in 2026.
• The last three Invested Capital figures came in at -$17.3 million (Q1 2026), -$62.2 million (Q4 2025), and -$64.7 million (Q3 2025), per Business Quant data.